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Abstract
The rat posterodorsal medial amygdala (MePD) links emotionally charged sensory stimuli to social behavior, and is part of the
supramedullary control of the cardiovascular system. We studied the effects of microinjections of neuroactive peptides
markedly found in the MePD, namely oxytocin (OT, 10 ng and 25 pg; n=6/group), somatostatin (SST, 1 and 0.05 mM; n=8
and 5, respectively), and angiotensin II (Ang II, 50 pmol and 50 fmol; n=7/group), on basal cardiovascular activity and on
baroreflex- and chemoreflex-mediated responses in awake adult male rats. Power spectral and symbolic analyses were
applied to pulse interval and systolic arterial pressure series to identify centrally mediated sympathetic/parasympathetic
components in the heart rate variability (HRV) and arterial pressure variability (APV). No microinjected substance affected
basal parameters. On the other hand, compared with the control data (saline, 0.3 mL; n=7), OT (10 ng) decreased mean AP
(MAP50) after baroreflex stimulation and increased both the mean AP response after chemoreflex activation and the high-
frequency component of the HRV. OT (25 pg) increased overall HRV but did not affect any parameter of the symbolic analysis.
SST (1 mM) decreased MAP50, and SST (0.05 mM) enhanced the sympathovagal cardiac index. Both doses of SST increased
HRV and its low-frequency component. Ang II (50 pmol) increased HRV and reduced the two unlike variations pattern of the
symbolic analysis (P,0.05 in all cases). These results demonstrate neuropeptidergic actions in the MePD for both the increase
in the range of the cardiovascular reflex responses and the involvement of the central sympathetic and parasympathetic
systems on HRV and APV.
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Introduction
The posterodorsal medial amygdala (MePD) is a
forebrain subcortical component of the ‘‘extended amygdala’’
(1) with a well-described role in the response to stressful
stimuli (2), hypothalamic neuroendocrine secretion (3), and
the display of social behaviors, such as aggressive and
reproductive behaviors in rats (4,5). The MePD is important
for higher-level, supramedullary control of cardiovascular
functions (6-8), and, in this sense, sends projections to the
central amygdaloid nucleus (CeA) and then to the A1
noradrenergic cells of the caudal ventrolateral medulla and
the nucleus of the solitary tract (NTS; 9,10). TheMePD is also
interconnected with other medial amygdala subnuclei that
innervate cardiovascular-related areas of the hypothalamus
(9,10) and the sympathetic/parasympathetic-related parts of
the periventricular hypothalamic zone (11). It is highly likely
that this integrated network modulates cardiovascular
responses to ensure appropriate hemodynamic responses
concomitant with the expression of social behaviors (7,8,12).
The involvement of the MePD in the regulation of heart
rate (HR) and arterial blood pressure (AP) were reported
under different methodological conditions. For example,
electrical stimulation of the MePD increased AP in mice
(13). Activation of the whole mousemedial amygdala (MeA)
after fear or aversive stress led to sympathetic activation
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and neurogenic hypertension (14,15), whereas bilateral
neurotoxic lesions of the posterior part of the MeA
attenuated the development of high AP levels in sponta-
neously hypertensive rats (16). Moreover, central control of
short-term reflexes of the cardiovascular system integrates
inputs from peripheral baroreceptors and chemoreceptors
and the sympathetic/parasympathetic output to the heart and
vascular beds (17). Microinjection of glutamate (2 mg/0.3 mL)
into the MePD of awake rats elicits a selective activation of
the central sympathetic adjustment to modulate the barore-
flex response, whereas microinjection of gamma-amino-
butyric acid (GABA; 61 ng/0.3 mL) activates the central
parasympathetic counterpart (8). Histamine (30 mg/0.3 mL
and 300 mg/0.3 mL) in the MePD shows more complex and
dose-dependent responses, with a lower dose modulating
part of the baroreflex response and a higher dose leading to
a decrease in the parasympathetic component of the HR
variability (HRV), an increase in the sympathetic/parasym-
pathetic balance at basal conditions, and impairment of the
chemoreflex bradycardic response (7).
It is notable that various neuroactive peptides can be
found in the MePD. Oxytocin (OT)-binding sites occur
in different MePD cellular columns (18), and local OT
modulates the neural processing of social odorants and
approach behavior (19). Somatostatin (SST) is found in the
MePD as well (20,21) and causes a dose-dependent
inhibition of the rat MeA, either directly or by activating
GABAergic synaptic transmission (21). There is also an
evident expression of the angiotensin II (Ang II) 1A receptor
in the MePD (22). These findings are worth noting because
OT reduces cardiovascular responses to acute stress in
rats (23) and modulates baroreceptor reflex responses
(24). SST modulates sympathetic and parasympathetic
cardiovascular actions and induces hypotension and
bradycardia (25). Ang II can increase AP due to centrally
mediated effects (26), acting in circumventricular organs or
in the NTS, either by activating the central sympathetic
nervous system or by elevating plasma vasopressin, norad-
renaline, and adrenaline levels (6,27). In rats, central Ang II
also blunts parasympathetic activity, reduces baroreflex
sensitivity (28), and stimulates chemoreflex responses
(29). However, it is not currently known whether there are
cardiovascular effects induced by these neuropeptides
when acting in the rat MePD.
Here, we studied the basal hemodynamic state and
reflex-mediated cardiovascular responses after microinjec-
tions of OT, SST, and Ang II into the MePD of awake male
rats. Baroreflex and chemoreflex responses were tested.
Power spectral and symbolic analyses were performed
to evaluate the central involvement of sympathetic
and parasympathetic components in the variability of the
HR and AP. We used the same methodological approach
previously described for the study of classical neurotrans-
mitter actions in the MePD (7,8, and references therein)
and found additional changes in the central control of
cardiovascular reflexes elicited by these neuropeptides
in this brain area, providing additional detail for better




Adult male Wistar rats (3-4 months old, body weight
250-300 g) were kept in groups under standard laboratory
conditions, with food and water ad libitum and room tem-
perature around 226C in a 12:12-h light-dark cycle (lights off
at 7:00 pm). All efforts were made to minimize the number
of animals and their suffering. Rats were manipulated
according to international laws for ethical care and use
(European Communities Council Directive of 24 November
1986, 86/609/EEC), conforming to national guidelines, and
experiments were approved by the Ethics Committee of
Universidade Federal de Cieˆncias da Sau´de de Porto
Alegre (protocol #05/029).
Implantation of the MePD cannula and vascular
catheters for hemodynamic evaluation
The experimental design is shown in Figure 1. Animals
were anesthetized with a combination of ketamine and
xylazine (90 and 10 mg/kg, ip, respectively) and were
stereotaxically implanted with a cannula (0.6 mm outer
diameter, OD) 2 mm above the right MePD, according to
the following coordinates: 3.3 mm posterior to the bregma,
Figure 1. Experimental design (in days) with
surgical, microinjection, cardiovascular recordings
and histological procedure schedules.
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3.6 mm lateral to the sagittal suture, and 5.7 mm below the
dura mater (adapted from Ref. 30; Figure 2). After that,
each rat received ketoprofen (3 mg/kg in 0.3 mL, ip), one
injection per day for 2 days.
After 5 days, animals were anesthetized as cited earlier
and had a polyethylene catheter [PE-10 soldered to a PE-50,
0.28 mm inner diameter (ID), Biocorp, Australia, filled with
sterile 0.9% NaCl (pH 7.4) and heparin] placed into the
abdominal aorta and another into the inferior vena cava
through the left femoral artery and vein, respectively. Each
catheter was tunneled subcutaneously and exteriorized
at the back of the rat neck. Gentamicin (2 mg/rat, im) was
Figure 2. A, Photomicrograph of a coronal section
of the ventral forebrain to show the microinjection
(MI) site where substances were microinjected,
diffused out and reached the posterodorsal medial
amygdala (MePD), without lesioning it directly. In
this case, the MePD was found approximately
3.30 mm below the bregma, lateral to the optic
tract (opt) and ventral to the stria terminalis (st).
Hematoxylin and eosin stain. B, Schematic draw-
ing of coronal sections of the ventral part of the rat
brain showing the MePD and the approximate
sites for the microinjections of saline, oxytocin,
somatostatin and angiotensin II (filled circles).
Non-target sites are indicated by filled squares.
All microinjections were administered to the right
MePD and the points represent the approximate
locale for drug spread. There are fewer points than
the number of animals studied due to overlapping
in the microinjection sites in different rats. No
evident signs of parenchymal lesions in the MePD
were found in the experimental groups.
Coordinates are in millimeters posterior to the
bregma (from 2.8 to 3.8 mm). MePV, poster-
oventral part of the medial amygdaloid nucleus.
Adapted from Ref. 30.
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injected at the end of this procedure. The next day, the
arterial catheter was attached to a 40-cm polyethylene tube
(PE-50, 0.5 mm ID, Biocorp), and a strain-gauge pressure
transducer (P23 Db, Gould Statham, USA) was used
for direct hemodynamic measurements. Signals passed
through a preamplifier (Hewlett-Packard 8805, Puerto Rico)
and were delivered to a microcomputer equipped with an
analog-to-digital converter board (CODAS, 1 kHz, Dataq
Instruments, USA). The recorded data were analyzed on a
beat-to-beat basis.
All rats of the control and experimental groups were
subjected to the same recording protocol. That is, after the
catheter was connected to the transducer, rats were allowed
to acclimate to a Plexiglas recording box (25615610 cm)
over 20 to 30 min while cardiovascular parameters were
being continuously monitored. Values of HR and AP were
obtained during the last 15 min of this period to provide
basal within group and between groups data to be com-
pared with the effects of microinjections into the MePD. All
recordings occurred during the morning (from 8:00 am to
12:00 noon) to avoid unpredictable circadian variations in
the results.
Immediately after these initial recordings, a microinjec-
tion needle (0.3 mm OD) was introduced into and 2 mm
below the intracerebral guide cannula. Animals were then
randomly assigned to 1 of 4 experimental groups that
were manually microinjected with 1) vehicle (saline, 0.3 mL,
n=7) as the control group; 2) OT (10 ng/0.3 mL and 25 pg/
0.3 mL, n=6 in both groups); 3) SST (1 mM/0.3 mL, n=8;
and 0.05 mM/0.3 mL, n=5); 4) Ang II (50 pmol/0.3 mL and
50 fmol/0.3 mL, n=7 in both groups). All drugs were
purchased from Sigma Chemical Co. (USA). These higher
and lower values of OT, SST, and Ang II proved to be
effective in inducing central effects when microinjected into
different brain areas (described in Ref. 6 and references
therein). The microinjection procedure wasmonitored by the
displacement of liquid and an air bubble inside the catheter
connected to a 2-mL Hamilton microsyringe (USA), lasted for
1 min, and the needle remained inside the cannula for an
additional minute to avoid reflux. After 4 min, new cardio-
vascular recordings were obtained and lasted for the next
15 min. Additional MePD microinjections were completed
before testing baroreceptor- and chemoreceptor-mediated
reflexes. Then, every rat received 3 microinjections of each
substance assigned to its experimental group as follows:
one to test the MePD microinjection effects on the HR and
AP values, one before testing the baroreflex responses, and
one before testing the chemoreflex responses. The order for
testing baroreflex or chemoreflex activities was randomly
chosen for each rat in all experimental groups. Obvious drug
carryover effects were avoided, and new recordings were
only started when hemodynamic values returned to baseline
levels and remained stable during the recording time (7,8).
Baroreflex and chemoreflex stimulation
Reflex responses were tested 5 min following each
MePD microinjection. Baroreflex-mediated changes were
measured during peak increases or decreases in mean
arterial pressure (MAP) after vena cava injection of a single
dose of phenylephrine (8 mg/0.1 mL, Sigma Chemical Co.),
or sodium nitroprusside (100 mg/0.1 mL, Sigma Chemical
Co.) dissolved in saline (8). These injections were made
manually and, in all experimental groups, at similar and
appropriate infusion rates, to lead to changes in MAP in the
range 10-30 mmHg with no evident artifactual activations.
Various data points served to compose sigmoidal curves.
All changes in MAP and HRweremeasured, and baroreflex
sensitivity was determined by fitting the MAP and HR
changes to a sigmoidal logistic equation, as follows:
HR=P1+P2/[1+exp P36(MAP–P4)] where P1 is the lower
HR plateau [in beats per minute (bpm)], P2 is HR range
between upper and lower curve plateaus (delta HR, in
bpm), P3 is a curvature coefficient that is independent of
range, and P4 is MAP at one-half of the HR range (MAP50,
in mmHg), which is also the point for the calculation of the
maximum gain. The upper plateau was calculated by the
sum of P1 and P2 (7,8, and references therein).
Chemoreflex sensitivity was tested under the same
methodological conditions, but after the administration of
increasing intravenous doses of potassium cyanide (KCN;
60, 100, 140, and 180 mg/kg; Merck, Germany). Injected
volumes ranged from 0.06 to 0.18 mL. Mean HR and
MAP were measured continuously 10 s before and 15 s
after each injection of these KCN doses. The inter-injection
interval for each dose of KCN was around 4 min, and a new
dose was administered only when appropriate HR andMAP
baselines had been reestablished (7,8).
Power spectral analysis and symbolic analysis
These analyses demonstrate the different components
in the variability of the HR and AP recordings and were
applied to the results of the experimental groups as long as
technically possible. For this reason, some results from the
Ang II groups were not sufficient for further analyses and
are shown only when they could be reliably done.
These methodological descriptions were reported
previously (7,8 and references therein). Briefly, power
spectral analysis was applied to pulse interval (PI) and
systolic arterial pressure (SAP) series. Tachograms
and systograms were created from AP signals through
the beat-to-beat PI and SAP, respectively. Frequency
domain analysis of HRV (PI variability) and AP variability
(APV) were obtained with an autoregressive algorithm on
stationary sequences of 200 beats that were randomly
chosen, but without artifacts, using the stationary test
based on very low quantification of oscillations. Spectral
estimation by the autoregressive model, using the residual
theorem, provides central frequency and associated power
with the additional advantage that, even with short seg-
ments of data, they can provide a reliable spectral resolu-
tion. HRV and APV correspond to the total power spectrum
of PI and SAP.
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The low-frequency (LF; 0.2-0.75 Hz) and high-fre-
quency (HF; 0.75-3.0 Hz) spectral components of PI and
SAP were expressed in both absolute (ms2 and mmHg2,
respectively) and normalized units (NU). NU were obtained
by calculating the power of LF and HF and correlating
them to the total power without the very low frequency
component (frequencies that were ,0.2 Hz). This method
estimates the center frequency and power of each relevant
oscillatory component and indicates the involvement of
the central control of the sympathetic/parasympathetic sys-
tems in the cardiovascular responses. The ratio between
LF and HF components (LF/HF) was considered a synthe-
tic expression of the sympathovagal balance. The coher-
ence between the PI and the SAP variability was assessed
by means of a cross-spectral analysis. The alpha index
was obtained from the square root of the ratio between the
R-R interval and the SAP variability within the LF ranges
and was calculated only when the magnitude of the
squared coherence exceeded 0.5 (range=0 to 1) in the
LF band. Using this alpha index for the LF component,
beat-to-beat values of the PI and the SAP were used to
estimate spontaneous baroreflex sensitivity.
Symbolic analysis was applied on the same sequences
of PI and SAP data. This method consisted of the scattering
of the time series over 6 bins, each identified by a number
(symbol) from 0 to 5. Symbolic series is a sequence of
symbols for each bin, converted into patterns of 3 symbols.
All 3 possible beat patterns are divided into 4 groups as
follows: 1) no variations (0V, i.e., three identical symbols),
2) one variation (1V, two identical symbols and 1 different),
3) two like variations (2LV), and 4) two unlike variations
(2UV). The 0V is a marker of sympathetic modulation, a 1V
pattern reflects sympathetic and parasympathetic modula-
tions, a 2LV pattern indicates sympathetic and parasympa-
thetic modulations with vagal predominace, and 2UV is
an exclusive marker of vagal modulation (see Ref. 31 and
references therein).
Histological procedure
At the end of the experiments, rats were deeply
anesthetized as described earlier and transcardially per-
fused with saline and 10% formalin solution. Brains were
cut into 60-mm thick sections using a vibratome (Leica,
Germany) and stained with hematoxylin and eosin. The
microinjection site was histologically determined and com-
pared to the images of an atlas (30). This microinjection
procedure was validated for accurate drug administration in
small brain regions (32) – further comments about the effects
of microinjected substances in the MePD can be found
elsewhere (7,8). Only those rats that had the microinjections
directed to the MePD were considered for further analysis.
Data from rats that had intraparenchimatous hemorrhage,
mechanical lesions in the MePD, or microinjections that
damaged the stria terminalis were not included.
Approximate sites for drug spread in the targeted area
are shown in Figure 2A and B. As described previously (8),
an inherent technical limitation of the present methodolog-
ical approach is that drugs may have affected all parts
of local neurons and glial cells, including both cell bodies
and their prolongments. The specific diffusion rate for each
of the substances microinjected into the MePD was not
directly evaluated, and the average radius of drug diffusion
was not estimated by virtue of comparing a dye with distinct
physicochemical properties with the microinjected drugs.
However, it is assumed that substances can diffuse an
average radius of 0.5 mm from the point of microinjection
(32). Here, it is also likely that the position of the guide
cannula for the microinjection let the substances spread
from the medial border of the MePD through its neuropil,
and the coarse axons of the optic tract, situated in the back
of the microinjection site, might have limited drug diffusion
outside the MePD.
Nevertheless, non-target groups were also included to
control for drug effects outside the intended area (n=7 rats
for each microinjected substance). Cannulae and micro-
injections reached the vicinity of the MePD in these non-
target groups, and their data served to evaluate possible
effects of the tested drugs in other medial amygdala
subnuclei, other adjacent amygdaloid nuclei, in the optic
tract, or in the ventral basal ganglia, all structures close to
the MePD (Figure 2).
Statistical analysis
The basic requirements for the use of parametric
analysis were assessed by the Kolmogorov-Smirnov and
Levene tests. After that, the values of HR, SAP, diastolic
AP (DAP), and MAP at basal conditions and the results of
HR and AP evoked by the chemoreceptor reflex response
were submitted to two-way analysis of variance (ANOVA)
for repeated measures. Data obtained after the stimulation
of the baroreflex were analyzed using one-way ANOVA.
The Newman-Keuls post hoc test was used for multiple
comparisons.
The normal distribution of data from spectral and
symbolic analyses was determined by the Bonferroni test.
After that, the results were analyzed using one-way ANOVA
followed by the Tukey test.WhenGaussian normality failed,
a Kruskal-Wallis test on ranks and the Dunn’s test were
performed. In all cases, the statistically significant level was
set a priori as P#0.05.
Results
Present results focus on the MePD results. To be
concise, the non-target control data did not reproduce in
any way the effects obtained in the experimental groups
microinjected with the different neuropeptides in the MePD
(ANOVA, P.0.05 in all cases; data not shown).
Hemodynamic status
Basal hemodynamic values were within normal ranges
for adult male rats recorded under laboratory conditions.
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No relevant statistical difference was found in the HR, SAP,
DAP, and MAP following microinjections of saline or OT,
SST, and Ang II (ANOVA, P.0.05 in all cases). There were
no lasting effects of the microinjections in any experimental
group, which provided stable baseline recordings prior to
the assessment of the baroreflex and the chemoreflex
responses (Table 1).
Effects of baroreflex activation
Reflex control of theHRwas analyzed by fitting sigmoidal
curves to different data points of each animal. Mean values
were calculated for each experimental group (Figure 3). The
MAP50, which describes theMAP value at one-half of the HR
range in the baroreflex curve, following the injections of
phenylephrine and sodium nitroprusside showed an over-
all statistical difference between groups [F(6,47)=3.37,
P,0.01]. The post hoc comparisons revealed that the
MePDmicroinjection of OT (10 ng) or SST (1 mM) promoted
a significant decrease in the MAP50, shifting the barocurve
to the left and to lower HR values when compared with the
results from the saline microinjected group (P,0.05 in both
cases).
An overall statistical difference was also found in the
maximum gain of the reflex responses when the AP was
increased by phenylephrine or decreased by sodium
nitroprusside when compared between the experimental
groups [F(6,47)=2.56, P,0.03], but post hoc comparisons
did not show differences between any tested substances
compared with saline. For the HR range [F(6,47)=1.29,
P=0.27], the lower plateau [F(6,47)=1.53, P=0.19] and
the upper plateau [F(6,47)=1.19, P=0.09] did not differ
between the experimental groups.
Effects of chemoreflex activation
Data for chemoreflex activation are shown in Figure 4.
There was a statistically significant difference in the HR after
injection of the increasing doses of KCN [F(3,123)=69.77,
P=0.01] and between experimental groups microinjected
into the MePD [F(6,123)=2.82, P=0.02], but no statis-
tical interaction was found between these two factors
[F(18,123)=1.51, P=0.09].
On the other hand, the values of MAP obtained after the
injection of the different doses of KCN reached statistically
significant levels [F(3,123)=17.26, P=0.01] and, although
data did not differ between the experimental groups
[F(6,123)=1.08, P=0.38], the interaction between these
two factors was significantly different [F(18,123)=2.22,
P,0.01]. The post hoc test showed that, compared with
saline, OT (10 ng) microinjected into the MePD led to a
marked increase in the MAP following KCN (180 mg/kg;
P,0.05). No other comparison showed a significant
Table 1. Basal hemodynamic data obtained before (control data) and after (test data) microinjections into the rat posterodorsal medial
amygdala of saline (0.3 mL, n=7), oxytocin (OT; 10 ng/0.3 mL and 25 pg/0.3 mL, n=6 in both groups), somatostatin (SST; 1 mM/
0.3 mL, n=8 and 0.05 mM/0.3 mL, n=5), or angiotensin II (Ang II; 50 pmol/0.3 mL and 50 fmol/0.3 mL; n=7 in both groups).
Groups SAP (mmHg) DAP (mmHg) MAP (mmHg) HR (bpm)
Control After Control After Control After Control After
Saline 136 ± 9.0 131.0 ± 12.7 90.1 ± 4.6 89.5 ± 9.3 111.6 ± 5.6 109.0 ± 10.1 360.2 ± 29.3 350.7 ± 31.9
OT (10 ng) 132.6 ± 11.2 135.7 ± 7.8 88.4 ± 4.9 88.5 ± 2.2 109.9 ± 4.9 111.4 ± 3.5 361.5 ± 25.8 375.7 ± 26.2
OT (25 pg) 131.7 ± 5.2 128.7 ± 6.6 93.7 ± 7.9 91.9 ± 9.4 111.9 ± 6.5 109.4 ± 8.8 370.7 ± 23.4 347.7 ± 12.5
SST (1 mM) 131.9 ± 4.0 135.4 ± 7.0 88.5 ± 3.8 91.6 ± 6.3 109.7 ± 3.3 112.7 ± 6.9 352.5 ± 39.6 365.9 ± 38.1
SST (0.05 mM) 131.5 ± 7.7 124.0 ± 6.8 94.1 ± 6.4 89.4 ± 5.9 111.4 ± 5.5 106.6 ± 6.3 351.8 ± 21.0 340.0 ± 25.4
Ang II (50 fmol) 134.0 ± 6.0 131.1 ± 8.5 94.8 ± 6.1 95.4 ± 10.4 113.5 ± 5.5 112.5 ± 9.5 354.7 ± 37.5 353.6 ± 53.3
Ang II (50 pmol) 134.4 ± 11.8 134.7 ± 9.2 94.0 ± 5.5 94.2 ± 5.3 113.5 ± 7.6 113.5 ± 6.7 354.0 ± 42.2 354.9 ± 39.1
Data are reported as means±SD. SAP: systolic arterial pressure; DAP: diastolic arterial pressure; MAP: mean arterial blood pressure;
HR: heart rate. No statistically significant differences were found comparing data between experimental groups (one-way ANOVA).
Figure 3. Plots showing the average values for the relationship
between mean arterial blood pressure (MAP) and heart rate (HR),
using logistic sigmoidal baroreceptor curve analysis, of rats that
received the following microinjections in the posterodorsal medial
amygdala: saline (0.3 mL, n=7), oxytocin (10 ng/0.3 mL and 25 pg/
0.3 mL, n=6 in both groups), somatostatin (1 mM/0.3 mL, n=8
and 0.05 mM/0.3 mL, n=5), or angiotensin II (50 pmol/0.3 mL and
50 fmol/0.3 mL; n=7 in both groups).
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statistical difference between the experimental groups and
the saline group (P.0.05).
Power spectral analysis
Power spectral analysis results are shown in Table 2 and
Figure 5. There were no statistically significant differences in
the SAP [F(5,33)=1.63; P=0.17], in the mean values of HR
[F(5,33)=2.01; P=0.10], in the absolute LF component
[F(5,33)=1.87; P=0.125], or in the absolute HF component
of the SAP between the experimental groups [F(5,33)=
1.41; P=0.24].
However, the HRV analysis showed a statistically
significant difference between experimental groups [F(5,33)
=4.50; P,0.05]. The post hoc comparison showed that
OT (25 pg), SST (1 and 0.05 mM), and Ang II (50 pmol) led
to increased values compared with saline (P,0.05 in all
cases). In addition, the LF component of the HRV, in NU,
presented a statistically significant difference between
the experimental groups [F(5,33)=2.61; P,0.05] and the
post hoc test indicated that SST (1 mM and 0.05 mM)
promoted an increase in this parameter compared with
saline (P,0.05 in both cases). There was also an overall
difference in the absolute power of the HF component of the
HRV [F(5,33)=2.65; P,0.05], and the post hoc compar-
ison showed that OT (10 ng) promoted an increase in this
parameter compared with saline (P,0.05).
The sympathetic/parasympathetic balance obtained
from the alpha index also showed a statistically significant
difference between experimental groups [F(5,33)=2,71;
P,0.05] and, specifically, SST (0.05 mM) promoted higher
values compared with saline (Newman-Keuls test, P,0.05).
Symbolic analysis
Results are presented in Table 3 and Figure 5. Com-
pared with control data, the microinjections of OT (10 ng
and 25 pg) and SST (1 and 0.05 mM) did not cause evident
effects (Newman-Keuls test, P.0.05), but there was a
significant decrease in the 2UV pattern after Ang II (50 fmol)
microinjection into the MePD when compared with saline
[F(5,34)=2.282, P,0.05; Newman-Keuls test, P,0.05].
Discussion
Our present results reinforce findings that the rat MePD
is a component of the central network that modulates
baroreceptor- and chemoreceptor-mediated cardiovascular
adjustments. These data match with the evident presence
of neuropeptides and their receptors in the MePD (18-22)
and indicate functional implications that deserve further
evaluation, as follows.
First, it is interesting that the tested neuropeptides
promoted long-lasting effects (in the order of minutes) when
microinjected into the MePD, as previously reported for
classical neurotransmitters [glutamate, GABA, and hista-
mine], which appears to be a particularity of this brain area
(7,8). In addition, the MePD contributes more to changes in
cardiovascular reflexes than in basal HR and AP levels. As
occurs for other amygdaloid nuclei (33), it is possible that
transmitter-mediated excitatory, inhibitory, and/or disinhib-
itory mechanisms in the MePD can promote a flexible,
dose- and context-dependent modulation of the central
control of sympathetic/parasympathetic output (6). We
also propose that the rat MePD is responsive to different
Figure 4. A, Heart rate (HR) and B, mean arterial blood pressure
(MAP) of the chemoreceptor reflex response induced by increas-
ing doses of potassium cyanide (KCN, from 60 to 180 mg/kg) in
rats that received microinjections into the posterodorsal medial
amygdala of saline (0.3 mL, n=7), oxytocin (OT; 10 ng/0.3 mL and
25 pg/0.3 mL, n=6 in both groups), somatostatin (SST; 1 mM/
0.3 mL, n=8 and 0.05 mM/0.3 mL, n=5), or angiotensin II (Ang II;
50 pmol/0.3 mL and 50 fmol/0.3 mL; n=7 in both groups). Data are
reported as means±SD. Data were submitted to the two-way
ANOVA test for repeated measures and the Newman-Keuls post
hoc test. InA, for HR: *P,0.01 comparedwith 60 mg/kg KCN in the
groupmicroinjected with saline. **P,0.01 compared with 60 mg/kg
KCN in the group microinjected with OT 10 ng. +P,0.01 com-
pared with 60 mg/kg KCN in the group microinjected with OT
25 pg. {P,0.01 compared with 60 mg/kg KCN in the group
microinjected with SST 0.05 mM. {P,0.05 compared with 60 mg/
kg KCN in the group microinjected with Ang II 50 pmol. In B, for
MAP: *P,0.01 compared with 60 mg/kg KCN in the group
microinjected with OT 10 ng. +P,0.05 compared with 140 mg/kg
KCN in the group microinjected with SST 1 mM. {P,0.05
compared with 180 mg/kg KCN in the group microinjected with
saline. {P,0.05 compared with 180 mg/kg KCN in the group
microinjected with OT 10 ng. Expanded and adapted from Ref. 6
with permission from Nova Science Publishers (USA).
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neurotransmitters and neuropeptides that code distinct
synaptic inputs for specific fine-tunings of centrally medi-
ated cardiovascular reflexes and the dynamic display of
behaviors in awake animals (7,8). It is now desirable to
determine how neurotransmitters and neuropeptides in the
MePD can modulate the activity of specific output pathways
that reach other brain areas related to central cardiovas-
cular control.
Second, all the neuropeptides tested here evoked a
higher HRV as revealed by the power spectral analysis. The
predominant central sympathetic or parasympathetic mod-
ulation of the cardiovascular system involves the balance
between the spectral components in favor of the LF or the
HF band, respectively (34). However, it is noteworthy that
OT microinjections into the MePD did not cause specific
effects on the parameters evaluated by the symbolic
analysis. Then, it is possible that higher absolute LF and
HF power values (after OT 25 pg and 10 ng, respectively)
can be explained by the increase in HRV itself and the
change of the HF peak value, which is also associated with
ventilatory components and might be correlated with an
increased respiratory rate following OT (10 ng) microinjec-
tion into the MePD. The participation of rat MePD in the
central control of breathing is currently unknown. This is a
working hypothesis that needs to be confirmed with other
methodological approaches and opens a new and interest-
ing line of research.
Indeed, OT can have site-specific roles on the central
modulation of cardiovascular responses instead of similar
and widespread actions. For example, although intrace-
rebroventricular injection of OT did not evoke significant
cardiovascular effects (35), unilateral microinjections of an
OT receptor antagonist in the NTS reduced the long-lasting
vasopressor and tachycardic responses elicited by local
microinjection of this neuropeptide (24). OT also coun-
teracted the vasodepressor and bradycardic responses
induced by glutamate in this nucleus (24). Data from the
CeA, a component of the extended amygdala, provided
another interpretation for the effects of OT (36). That is, OT
microinjected into the CeA promoted an elevation in plasma
corticosterone, but not epinephrine and norepinephrine. At
the same time, the induction of a tachycardic response was
attributable to a somatic-sympathetic/parasympathetic cou-
pling rather than to a genuine ‘‘autonomic’’ activation (36).
Here, the microinjection of OT into theMePD also appeared
to affect central cardiovascular control only indirectly.
Otherwise, microinjection of SST into the MePD caused
an increase in the HRV suggestive of a central sympathetic
and parasympathetic coactivation. Because this finding was
also accompanied by an increase in the LF (in NU), they
rather point to changes in the central sympathetic regulation.
This increase in the HRV was also accompanied by a higher
alpha index, which indicates the relationship between the LF
components of the HRV and the APV along with an increase
in baroreflex sensitivity. The precise mechanism by which
SST exerts its effects in the MePD still remains to be
established. SST inhibits the presynaptic release of gluta-
mate, activates potassium channels, and inhibits voltage-
gated calcium channels via sst2 or sst5 receptors (37 and
references therein). SST can also promote an inhibitory
action by acting directly on its receptors or indirectly via
GABAergic synapses in the MeA (21). From our present
results, SST induced a central sympathetic effect, whereas,
comparatively, GABA in the MePD decreased the upper
Table 2. Cardiovascular parameters of power spectral analysis calculated from sampled data of rats that receivedmicroinjections into the
posterodorsal medial amygdala of saline (0.3 mL), oxytocin (OT; 10 ng/0.3 mL and 25 pg/0.3 mL), somatostatin (SST; 1 mM/0.3 mL and











Ang II 50 pmol
(n=7)
HRV (ms2) 13.35 ± 4.18 29.34 ± 9.57 46.75 ± 18.7* 49.80 ± 16.90* 58.81 ± 39.59* 50.78 ± 22.23*
fLF (Hz) 0.54 ± 0.10 0.50 ± 0.10 0.51 ± 0.12 0.45 ± 0.10 0.42 ± 0.07 0.56 ± 0.10
LF (ms2) 0.49 ± 0.26 1.51 ± 0.89 6.48 ± 6.21* 3.04 ± 2.62 5.70 ± 4.88 3.80 ± 3.59
LF (NU) 9.24 ± 3.55 13.45 ± 6.41 15.53 ± 6.63 19.66 ± 8.17* 22.38 ± 11.86* 14.46 ± 7.66
fHF (Hz) 1.84 ± 1.37 1.87 ± 10.95* 1.76 ± 151 1.70 ± 1.68 1.67 ± 1.21 1.65 ± 1.29
HF (ms2) 4.68 ± 2.01 11.59 ± 10.64* 30.16 ± 25.36 12.22 ± 5.81 17.02 ± 5.69 24.98 ± 22.46
HF (NU) 87.38 ± 5.12 80.76 ± 12.09 84.39 ± 6.67 80.31 ± 8.16 77.62 ± 11.86 84.11 ± 8.02
LF/HF 0.11 ± 0.04 0.18 ± 0.11 0.19 ± 0.09 0.26 ± 0.13 0.32 ± 0.25 0.18 ± 0.11
APV (mmHg2) 8.84 ± 3.48 20.16 ± 10.70 10.54 ± 5.89 15.80 ± 8.82 12.32 ± 5.98 17.46 ± 12.55
VLF (mmHg2) 5.78 ± 4.09 11.07 ± 8.76 3.62 ± 2.84 8.90 ± 9.22 8.71 ± 7.13 10.13 ± 12.49
LF (mmHg2) 1.72 ± 0.77 5.78 ± 3.31 4.04 ± 3.18 4.20 ± 3.16 2.73 ± 1.79 3.60 ± 1.93
HF (mmHg2) 1.33 ± 0.43 3.24 ± 2.38 2.86 ± 3.26 2.70 ± 1.02 0.88 ± 0.36 2.29 ± 2.06
Alpha index (ms/mmHg) 0.53 ± 0.11 0.53 ± 0.14 1.16 ± 0.52 1.09 ± 0.79 1.56 ± 0.65* 1.29 ± 0.93
Data are reported as means±SD. HRV: heart rate variability; fLF: central low frequency; fHF: central high frequency; LF: low frequency
power; HF: high frequency power; APV: arterial pressure variability; VLF: very low frequency power. * P,0.05, compared to saline
(one-way ANOVA and the Tukey post hoc test or the Kruskal-Wallis test and the Dunn’s post hoc test).
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plateau of the baroreflex curve and induced higher values
of HRV linked with the central parasympathetic control
of the cardiovascular system (8). Therefore, these findings
demonstrate non-overlapping effects of SST and GABA on
cardiovascular responses when acting in the rat MePD.
Finally, microinjection of Ang II into the MePD increased
the HRV, did not affect power spectral components, but
reduced the 2UV pattern of the symbolic analysis, which
Figure 5. Power spectrum and symbolic analysis
applied to a time series of cardiovascular pa-
rameters of rats. The columns show the pulse
interval series, power spectrum and the symbolic
pattern distribution for the data obtained from the
experimental groups that received microinjections
into the posterodorsal medial amygdala with A,
saline (0.3 mL, n=7), B, oxytocin 10 ng and C,
25 pg (n=6 in both groups),D, somatostatin 1 mM
(n=8) and E, 0.05 mM (n=5), or F, angiotensin II
50 pmol (for the power spectral analysis) and
50 fmol (for the symbolic analysis; n=7 in both
groups). Values are from representative samples
of each experimental group. Mean values for all
studied animals are shown in Tables 2 and 3.
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was linked to cardiac vagal activity in pharmacological tests
(38). In the group microinjected with 50 pmol ANG II, it is
also possible that the lower bradycardic response produced
by pressure increase was related to the blunting of the
parasympathetic component, and the higher baroreflex gain
observed could be associated with the higher tachycardic
response after AP reduction. Microinjection, electrophysio-
logical, and lesion studies demonstrate complex interactions
and multiple sites for the action of Ang II on cardiovascular
control and in different brain areas (26-29). It is interesting
that AT1A receptors are involved in neuronal activation
and cardiovascular change after an olfactory-mediated psy-
chosocial stress in mice (39). Acting in the MeA, Ang II
might inhibit stress-induced aversive responses (39). How-
ever, no strain difference (between spontaneously hyper-
tensive and normotensive Wistar male rats) was identified
in c-Fos immunoreactivity in the MeA after aversive air jet
or air noise stress stimulation (40). Then, it is possible
that different species and/or types and intensity of sen-
sory stimulation can trigger the Ang II-evoked responses.
Marked central Ang II actions on the cardiovascular
system, partly stimulating sympathetic responses (27),
were not found after its microinjection into the MePD.
Rather, we found a central parasympathetic effect and,
in agreement with NTS data (29), Ang II in the MePD
potentiated the chemoreflex-mediated decrease in HR
frequency. These new findings add and expand the idea
of site-specific effects of Ang II on central cardiovascular
control and reinforce the multiple modulatory actions of the
MePD.
In summary, our work provides additional data for MePD
modulation of the baroreflex and chemoreflex cardiovascu-
lar responses in awake rats. Local microinjections promoted
neuropeptidergic-selective responses and involved the
central activation of the sympathetic and parasympathetic
effector systems. This MePD plastic capacity could provide
the animal with a dynamic mechanism of cardiovascular
control suitable for the ongoing demands of social be-
haviors, for which the MePD is a relevant component in
integrated brain circuits (2-6,9-11). Besides the adjustment
of homeostatic responses, these neuropeptidergic actions in
the MePD can also be involved in the pathophysiology of
cardiovascular diseases, such as hypertension (14-16), a
possibility that deserves further studies as well.
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